[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0000338A3 - Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them - Google Patents

Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
EP0000338A3
EP0000338A3 EP78100191A EP78100191A EP0000338A3 EP 0000338 A3 EP0000338 A3 EP 0000338A3 EP 78100191 A EP78100191 A EP 78100191A EP 78100191 A EP78100191 A EP 78100191A EP 0000338 A3 EP0000338 A3 EP 0000338A3
Authority
EP
European Patent Office
Prior art keywords
isoxazolo
preparation
pharmaceutical compositions
compositions containing
pyridine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78100191A
Other versions
EP0000338A2 (en
EP0000338B1 (en
Inventor
Povl Krogsgaard-Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of EP0000338A2 publication Critical patent/EP0000338A2/en
Publication of EP0000338A3 publication Critical patent/EP0000338A3/en
Application granted granted Critical
Publication of EP0000338B1 publication Critical patent/EP0000338B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
EP78100191A 1977-06-20 1978-06-19 Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them Expired EP0000338B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20
GB2574077 1977-06-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP80106498.1 Division-Into 1980-10-23
EP80106497.3 Division-Into 1980-10-23

Publications (3)

Publication Number Publication Date
EP0000338A2 EP0000338A2 (en) 1979-01-24
EP0000338A3 true EP0000338A3 (en) 1979-06-27
EP0000338B1 EP0000338B1 (en) 1981-11-25

Family

ID=10232513

Family Applications (4)

Application Number Title Priority Date Filing Date
EP78100190A Withdrawn EP0000167A1 (en) 1977-06-20 1978-06-19 1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them.
EP80106497A Withdrawn EP0027279A1 (en) 1977-06-20 1978-06-19 Isoxazolo(5,4-C)pyridines
EP80106498A Withdrawn EP0028017A1 (en) 1977-06-20 1978-06-19 3-Piperidinone-4-carboxylic acid derivatives
EP78100191A Expired EP0000338B1 (en) 1977-06-20 1978-06-19 Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP78100190A Withdrawn EP0000167A1 (en) 1977-06-20 1978-06-19 1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them.
EP80106497A Withdrawn EP0027279A1 (en) 1977-06-20 1978-06-19 Isoxazolo(5,4-C)pyridines
EP80106498A Withdrawn EP0028017A1 (en) 1977-06-20 1978-06-19 3-Piperidinone-4-carboxylic acid derivatives

Country Status (14)

Country Link
US (2) US4278676A (en)
EP (4) EP0000167A1 (en)
JP (2) JPS5436290A (en)
AT (1) AT368505B (en)
AU (2) AU3724478A (en)
CA (1) CA1107736A (en)
DK (2) DK270378A (en)
ES (2) ES470912A1 (en)
FI (2) FI64376C (en)
IE (1) IE47200B1 (en)
IT (2) IT7868449A0 (en)
NO (3) NO152049C (en)
NZ (1) NZ187615A (en)
ZA (2) ZA783493B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145473A1 (en) * 1980-11-27 1982-08-26 Kefalas A/S, Koebenhavn-Valby 2-Substituted 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-one compounds, processs for their preparation and medicaments containing them
DE3145474A1 (en) * 1980-11-27 1982-09-02 Kefalas A/S, Koebenhavn-Valby 3-Substituted 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine compounds, process for their preparation and medicaments containing them
EP0083378A1 (en) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tetrahydronicotinamide derivatives, a process for producing the same and a pharmaceutical composition comprising the same
GB8314391D0 (en) * 1983-05-24 1983-06-29 Kefalas As Heterocyclic compounds
IT1228426B (en) * 1987-07-20 1991-06-17 Ausimont Spa HETEROCYCLIC PEROXIDE
US4859666A (en) * 1988-07-06 1989-08-22 Bristol-Myers Company THAZ derivatives for enhancement of cerebral function
CN1043051C (en) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 Process for producing a hydrowax
EP2145620A3 (en) 2003-06-25 2010-03-17 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (en) * 2003-09-05 2005-11-02 Lundbeck & Co As H METHOD OF ELABORATION OF 4,5,6,7 TETRAHYDROISOXAZOL [5,4-C] PIRIDIN-3-OL (THIP)
PT1691811E (en) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
WO2005079851A2 (en) * 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP2292222A1 (en) 2005-01-28 2011-03-09 H. Lundbeck A/S Polymorphic Forms of a GABAA Agonist
US20080262029A1 (en) * 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Regulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (en) * 2014-04-11 2015-10-14 天津药物研究院 Preparation method of aminomethyl hydroxyisooxazole analogue
JP2017516868A (en) 2014-06-06 2017-06-22 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. How to increase persistent suppression and treat secondary insomnia
JP6735284B2 (en) 2015-03-24 2020-08-05 ハー・ルンドベック・アクチエゼルスカベット Production of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol
WO2017015049A1 (en) 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
KR102518846B1 (en) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. Methods and compositions for the treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
KR20210062662A (en) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. Use of Gaboksadol for the treatment of Tourette's syndrome, ticks and stuttering
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114292224B (en) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 Cannabidiol-2- (N-acetyl) piperidine acid ester and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (en) * 1972-05-04 1973-11-15 Bayer Ag 1,2,5,6-tetrahydropyridines - prepd from corresp 1-benzyl tetrahydropyridines and phosgene
DK62791A (en) * 1991-04-09 1992-11-09 Tulip Int As PROCEDURE FOR SALTING MEAT AND PLANT FOR USE IN EXERCISE OF THE PROCEDURE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACTA CHEMICA SCANDINAVICA B28, Pages 533-38 (1974) *
CHEMICAL ABSTRACTS 84, 159505z (1976) *
CHEMICAL ABSTRACTS 88, 37672p (1978) & Acta Chemica Scandinavica B31 (7), 584-8 (1977) *
NATUR (London) 268 (5615) 53-5 (1977) *

Also Published As

Publication number Publication date
JPS5436290A (en) 1979-03-16
IE47200B1 (en) 1984-01-11
NO152049C (en) 1985-07-24
EP0000338A2 (en) 1979-01-24
AU3729878A (en) 1980-01-03
DK270378A (en) 1978-12-21
FI781955A (en) 1978-12-21
IT7868450A0 (en) 1978-06-20
IT7868449A0 (en) 1978-06-20
ES470912A1 (en) 1979-02-01
FI64376B (en) 1983-07-29
IT1159739B (en) 1987-03-04
JPS5436275A (en) 1979-03-16
EP0027279A1 (en) 1981-04-22
CA1107736A (en) 1981-08-25
ZA783493B (en) 1979-06-27
US4278676A (en) 1981-07-14
NO782128L (en) 1978-12-21
ES470913A1 (en) 1979-02-01
NZ187615A (en) 1981-12-15
EP0028017A1 (en) 1981-05-06
ATA448678A (en) 1982-02-15
NO792839L (en) 1978-12-21
FI64376C (en) 1983-11-10
AU521040B2 (en) 1982-03-11
US4301287A (en) 1981-11-17
AT368505B (en) 1982-10-25
IE781234L (en) 1978-12-20
EP0000167A1 (en) 1979-01-10
FI781954A (en) 1978-12-21
NO782127L (en) 1978-12-21
NO152049B (en) 1985-04-15
DK270278A (en) 1978-12-21
ZA783492B (en) 1979-06-27
AU3724478A (en) 1980-01-03
EP0000338B1 (en) 1981-11-25

Similar Documents

Publication Publication Date Title
EP0000338A3 (en) Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them
DE2861316D1 (en) Thienothiazine derivatives, their preparation and compositions containing them
IL56206A0 (en) New 1,2-benzothiazine-1,1-doxide derivatives, their preparation and pharmaceutical compositions containing them
IL54842A (en) 1-piperidino-phthalazine derivatives,their preparation and pharmaceutical compositions containing them
IL49702A (en) Thieno(2,3-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them
IL49405A (en) Substitutet 4,5,6,7-tetrahydrothieno(i8o-c)(or(o8i-c)pyridinol derivatives, their preparation and therapeutic compositions containing them
IL56155A (en) Substituted alkanoylanilide derivatives,their preparation and pharmaceutical compositions comprising them
IL55906A0 (en) Novel erythromycine derivatives,their preparation and phararmaceutical compositions containing them
IL64759A0 (en) Furo-(3,4-c)pyridine derivatives,their preparation and pharmaceutical compositions containing them
IL55770A (en) 4-phenyl-2-acylaminothiazole derivatives,their preparation and immunostimulant compositions containing them
IL55242A0 (en) Novel pyridine derivatives,their preparation and pharmaceutical compositions containing them
IL54519A0 (en) 2-diarylalkyl-1-azabicyclo (2,2,2) octanes, their preparation and pharmaceutical compositions containing them
IL55765A (en) Dehydropyridine derivatives,their preparation and pharmaceutical compositions containing them
IL52997A (en) 6-substituted-3-amino-4-phenyl-1h-pyrazolo(3,4-b)pyridine derivatives, their preparation and pharmaceutical compositions containing them
IL54535A0 (en) Novel -lactam derivatives, their preparation and pharmaceutical compositions containing them
IL53857A0 (en) New aminoalkoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
IL55813A0 (en) Movel triazile derivatives, their preparation and pharmaceutical compositions containing them
IL54814A (en) 5,11-dihydro-11(piperazin-1-yl-alkanoyl)-6h-pyrido(2,3-b) (1,4)benzoidiazepin-6-one derivatives,their preparation and pharmaceutical compositions containing them
IL61614A (en) Ergoline derivatives,their preparation and pharmaceutical compositions containing them
IL54287A0 (en) New thienopyridine derivatives, their preparation and pharmaceutical compositions containing them
IL55894A (en) 1-alkylenedithia (or oxathia) benzyl-4-heteroaryl-piperazine derivatives,their preparation and pharmaceutical compositions containing them
IL54547A0 (en) Novel pyridazinone derivatives, their preparation and pharmaceutical compositions containing them
IL53766A0 (en) 4-diphenylmethylene-1-hydroxybenzyl-piperidine derivatives, their preparation and pharmaceutical compositions containing them
IL55857A (en) Benzodioxanylcarbonyl-piperazinoquinazoline derivatives,their preparation and pharmaceutical compositions containing them
IL54328A (en) Substituted pyrido(2,1-b)quinazoline-11-one derivatives,their manufacture and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

REF Corresponds to:

Ref document number: 2861342

Country of ref document: DE

Date of ref document: 19820128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19820630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19830609

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19840612

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19840629

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19840630

Year of fee payment: 7

Ref country code: BE

Payment date: 19840630

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19840730

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19860630

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19870620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19870630

BERE Be: lapsed

Owner name: H. LUNDBECK & CO. A/S

Effective date: 19870630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19880101

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19880226

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19880301

GBPC Gb: european patent ceased through non-payment of renewal fee
REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19890630

EUG Se: european patent has lapsed

Ref document number: 78100191.2

Effective date: 19880711

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT